Trade Tracker: Steve Weiss buys Humana
Steve Weiss, founder and managing partner at Short Hills Capital Partners, joins CNBC's “Halftime Report” to explain why he's buying Humana now.
Humana Stock Plunges as Insurer's Medicare Plan Ratings Plummet
Shares of health insurance provider Humana (HUM) plunged to their lowest level since 2020 after a large share of its Medicare offerings were downgraded by the Centers for Medicare and Medicaid Services (CMS).
Humana Inc (HUM) Trading Down 17.63% on Oct 2
Shares of Humana Inc (HUM, Financial) fell 17.63% in mid-day trading on Oct 2. The stock reached an intraday low of $213.31, before recovering slightly to $230.18, down from its previous close of $279.45.
Humana shares tumble on lower Medicare Advantage quality rating
CNBC's Bertha Coombs joins 'Squawk on the Street' to discuss why Humana is plunging today.
Humana's stock falls after Medicare Advantage rating suffers cut from Centers for Medicare and Medicaid Services
Humana's stock was headed for another sharp selloff on Tuesday, toward a more than four-year low, after the government cut its rating on one of the health insurer's large Medicare Advantage plans because it missed some performance measures.
Humana Stock Sinks on Medicare Advantage Troubles
Worries mount about the company's Medicare Advantage program.
Humana says members in its highly rated Medicare Advantage plans fell for 2025
Humana said the total members enrolled in its highly rated Medicare Advantage plans for people aged 65 years and above have reduced for 2025, sending the insurer's shares down about 12% in premarket trading.
2 Cheap Stocks Top Managers Have Been Buying
A couple of the best fund managers like these undervalued stocks.
Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.
Humana and Interwell Health Expand Value-Based Support to Florida
HUM and Interwell Health add Florida to their value-based kidney care program in a bid to improve health outcomes.
Humana: A Beaten-Down Health Care Stock to Re-Emerge as Inflation Fades
Humana's stock has faced a sharp sell-off, but fundamentals remain strong, with a potential 40% to 50% upside within 24 months as headwinds fade.
Humana's Falling Share Price Gives Investors An Opportunity
Humana has slid 10% due to exiting 13 markets, raising investor concerns, but remains attractive due to strong profitability and management alignment with investor interests. Despite trailing the S&P 500, Humana's core profitability is impressive, with NOPAT rising even as GAAP net income declined. Executive compensation tied to ROIC ensures management is incentivized to create value, making Humana a good long-term investment.
